Keywords :
Antibodies, Monoclonal; Antirheumatic Agents; Immunoglobulin Fab Fragments; Immunoglobulin G; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; adalimumab; golimumab; infliximab
Abstract :
[en] Biological therapies consisting of monoclonal antibodies and soluble receptors
have revolutionized the care of rheumatologic patients. These therapies ensued
from a better understanding of the physiopathology of rheumatologic disorders.
Most of the latter have been concerned: rheumatoid arthritis (for about 10
years), psoriatic arthritis and ankylosing spondilitys (for more or less five
years). Rheumatology was among the first disciplines to make use of these
advances; it continues to benefit from the results of intense research efforts.
These developments request from clinicians an increased expertise in immunology.
Scopus citations®
without self-citations
0